Immunohistochemistry in Lung Cancer: What It Reveals and Why It Matters

How Immunohistochemistry Works in Lung Cancer Diagnosis

Immunohistochemistry, or IHC, applies antibodies to thin slices of tissue to detect specific proteins. In lung cancer, these protein signals reveal whether a tumor is small cell or non-small cell, which subtype it belongs to, and whether certain genetic changes are present. Pathologists rely on IHC when biopsy samples are small or when morphology alone cannot distinguish between closely related cancers. The technique shapes treatment decisions by confirming diagnosis and ruling out mimics, such as metastases from other organs.

The Antibody-Based Detection Process

After a tissue sample is fixed and stained with hematoxylin and eosin, a pathologist selects a panel of antibodies. Each antibody binds to a target protein, and a detection system produces a visible color change at the site. Positive staining indicates the protein is present; negative staining means it is not. The pattern, intensity, and percentage of stained cells are all scored. In lung cancer, scoring follows standardized thresholds so results remain consistent across laboratories.

Common IHC Markers Used in Lung Cancer Classification

No single marker diagnoses lung cancer alone. Panels combine markers to separate subtypes and exclude differential diagnoses. The most frequently used antibodies target proteins linked to lung lineage, neuroendocrine differentiation, and specific molecular alterations.

• TTF-1 (Thyroid Transcription Factor-1): Positive in most lung adenocarcinomas and small cell lung cancers. Helps confirm a lung primary.
• Napsin A: Another marker of lung adenocarcinoma. Often paired with TTF-1 for greater sensitivity.
• p40 and p63: Squamous cell markers. Positive staining supports a squamous cell carcinoma diagnosis.
• CK5/6: A cytokeratin associated with squamous differentiation.
• Neuroendocrine markers (Synaptophysin, Chromogranin, CD56): Used when small cell carcinoma or large cell neuroendocrine carcinoma is suspected.
• PD-L1: Measures the level of programmed death-ligand 1 on tumor cells, which informs immunotherapy eligibility.
• ALK and ROS1 (with companion tests): IHC can screen for ALK rearrangements; ROS1 often requires a separate break-apart assay.

When IHC Is Ordered and What It Answers

Pathologists use IHC in several clinical scenarios. A biopsy showing poorly differentiated cells needs a lineage determination — is it a carcinoma, a lymphoma, or a sarcoma? IHC panels answer this. For confirmed non-small cell lung cancer, IHC distinguishes adenocarcinoma from squamous cell carcinoma, which affects surgical and systemic therapy choices. In advanced disease, IHC for PD-L1 and ALK guides first-line treatment selection. When a tumor has spread to the lung from another site, markers such as Napsin A, TTF-1, and p40 help confirm or exclude a lung origin.

Limitations and Pitfalls of IHC in Lung Cancer

IHC is powerful but imperfect. Staining can be weak or false-positive due to fixation issues or cross-reactivity. Some markers, like TTF-1, can be positive in thyroid carcinomas, so clinical context is essential. Results depend on antibody clone, staining protocol, and pathologist interpretation. For this reason, laboratories follow quality assurance programs and validated protocols. When IHC yields ambiguous findings, reflex testing with molecular methods such as fluorescence in situ hybridization or next-generation sequencing may follow.

IHC in the Age of Precision Medicine

Targeted therapies and immune checkpoint inhibitors have made precise lung cancer classification more urgent. IHC provides a rapid, cost-effective bridge between a tissue diagnosis and actionable treatment. While molecular profiling identifies specific driver mutations, IHC remains the frontline tool for subtype classification, PD-L1 assessment, and screening for protein-level abnormalities. Integrating IHC results with imaging, clinical history, and molecular data gives the treating team the fullest picture of the disease.

IHC does not replace molecular testing, but it directs it. An ALK-positive result by IHC prompts confirmatory molecular analysis, and a PD-L1 score determines whether immunotherapy should be tried first. In both cases, the initial IHC staining on the pathology slide is the step that starts the treatment pathway.

For patients, understanding IHC results can feel abstract, yet these tests directly shape what treatment comes next. A confirmed subtype, a PD-L1 level, or an ALK-positive result all narrow the options to therapies most likely to help. Asking the care team to walk through the IHC report — what each marker means and how it factors into the plan — is a practical way to take part in treatment decisions.